Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition.

doi:10.1038/nm.4040

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition.

Nature medicine - 1 Mar 2016

Hata Aaron N, Niederst Matthew J, Archibald Hannah L, Gomez-Caraballo Maria, Siddiqui Faria M, Mulvey Hillary E, Maruvka Yosef E, Ji Fei, Bhang Hyo-eun C, Krishnamurthy Radhakrishna Viveksagar, Siravegna Giulia, Hu Haichuan, Raoof Sana, Lockerman Elizabeth, Kalsy Anuj, Lee Dana, Keating Celina L, Ruddy David A, Damon Leah J, Crystal Adam S, Costa Carlotta, Piotrowska Zofia, Bardelli Alberto, Iafrate Anthony J, Sadreyev Ruslan I, Stegmeier Frank, Getz Gad, Sequist Lecia V, Faber Anthony C, Engelman Jeffrey A

Abstract excerpt

Although mechanisms of acquired resistance of epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancers to EGFR inhibitors have been identified, little is known about how resistant clones evolve during drug therapy. Here we observe that acquired resistance caused by the EGFR(T790M) gatekeeper mutation can occur either by selection of pre-existing EGFR(T790M)-positive clones or via genetic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Cycle

Share to Cell Survival

Share to Drug Resistance, Neoplasm

Share to Gefitinib

Share to In Vitro Techniques

Share to Protein Kinase Inhibitors

Share to Quinazolines

Source

Open in PubMed Open full text

Identifiers

PMID: 26828195
DOI: 10.1038/nm.4040
PMCID: PMC4900892

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition.PMID 26828195Read ↗

Early Steps of Resistance to Targeted Therapies in Non-Small-Cell Lung CancerSemantic proximity Read ↗

Mechanisms of Acquired Resistance and Tolerance to EGFR Targeted Therapy in Non-Small Cell Lung CancerSemantic proximity Read ↗

Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation--diversity, ductility, and destiny.Semantic proximity Read ↗

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.Semantic proximity Read ↗

Tumor Clonality and Resistance Mechanisms in EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Implications for Therapeutic SequencingSemantic proximity Read ↗

Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with EGFR Mutations.Semantic proximity Read ↗

Host-Dependent Phenotypic Resistance to EGFR Tyrosine Kinase Inhibitors.Semantic proximity Read ↗

Dynamic Changes and Drug-Induced Selection of Resistant Clones in a Patient With EGFR-Mutated Adenocarcinoma That Acquired T790M Mutation and Transformed to Small-Cell Lung Cancer.Semantic proximity Read ↗

Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench.Semantic proximity Read ↗

APOBEC3 activity promotes the survival and evolution of drug-tolerant persister cells during acquired resistance to EGFR inhibitors in lung cancerSemantic proximity Read ↗

Resistance of Lung Cancer to EGFR-Specific Kinase Inhibitors: Activation of Bypass Pathways and Endogenous MutatorsSemantic proximity Read ↗

Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressures.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.